Juvenile Arthritis - A Niche In The Market

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2005-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). Pediatric rheumatology is a growing specialty that offers high unmet need in terms of effective well-tested treatments. Rheumatic diseases remain a significant cause of chronic illness in children, with juvenile arthritis one of the most prevalent types.


Scope

  • Outline of the various juvenile arthritis classifications and guidelines
  • Insight into the use of key drug classes including disease modifying and pain killing treatments
  • Assess the future product positioning and life-cycle management strategies as commercially viable strategies are proposed for drug development in JIA
  • Read the latest data for novel products in clinical trials for this indication


    • Report Highlights
    Classifications for juvenile arthritis are often dissimilar, and vary from the US to the EU. The International League for Arthritis Research (ILAR) has outlined a definitive Juvenile Idiopathic Arthritis (JIA) definition which is now being adopted in clinical trials.

    Pathology differs from adult RA mechanisms, but IL-1 and IL-6 appear to be key mediators and inhibition of each has shown promise in JIA. Kineret (anakinra) the only IL-1 inhibitor currently available, does not appear to be in development for JIA, but Actemra (tocilizumab) is expected to launch in both adult and juvenile RA in the near future.

    Orphan designation qualifies the sponsor of the product for tax credit and marketing incentives, and all three biologic TNF-inhibitors currently have orphan designation in the US but only Enbrel (etanercept) is approved in this indication. Novel products are advised to apply for this designation.


    Reasons to Purchase

  • Identify the key definitions and subtypes involved in juvenile arthritis and evaluate the latest guidelines and treatment algorithms
  • Develop commercial strategies for juvenile arthritis approval
  • Understand the latest trial data from novel biologic therapies such as IL-6 inhibitor tocilizumab and IL-1 inhibitor anakinra

    • Table of Contents

    Other users found this report page using the following search terms: Juvenile Arthritis rheumatoid arthritis autoimmune juvenile arthritis jia actemra enbrel remicade biologics approval humira il6

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.